DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Treatment of Binge Eating Disorder

Not Applicable

Completed

Conditions: Bulimia
Obesity

First Posted Date: 2002-06-19

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 180

Registration Number: NCT00039936

Locations: 🇺🇸
NRI, Fargo, North Dakota, United States

Hepatitis C Antiviral Resistance in African-Americans

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2002-06-10

Last Posted Date: 2017-08-03

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 401

Registration Number: NCT00038974

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Miami School of Medicine, Miami, Florida, United States

and more 5 locations

Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Brachytherapy

First Posted Date: 2002-06-07

Last Posted Date: 2018-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00039624

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Hodgkin Disease
NonHodgkin Lymphoma
Mixed Lymphoproliferative Disease

First Posted Date: 2002-06-07

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1836

Registration Number: NCT00039676

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
NIH National Cancer Institute - Shady Grove, Rockville, Maryland, United States

Diabetes Prevention Program Outcomes Study

Phase 3

Active, not recruiting

Conditions: Diabetes Mellitus
CVD
Cancer

Interventions: Behavioral: DPPOS Group Lifestyle
Behavioral: DPPOS Boost Lifestyle
Drug: Metformin
Behavioral: Intensive Lifestyle Group Session

First Posted Date: 2002-06-05

Last Posted Date: 2021-12-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 2779

Registration Number: NCT00038727

Locations: 🇺🇸
George Washington University, Rockville, Maryland, United States

Combination Drug Treatment of Pediatric HIV Infection

Phase 1

Completed

Conditions: HIV Infection

First Posted Date: 2002-05-22

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00001818

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

Phase 2

Completed

Conditions: HIV Infection

First Posted Date: 2002-05-22

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00001688

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Phase 1

Completed

Conditions: Advanced Esophageal Cancers
Pleural Mesotheliomas
Primary Small Cell Lung Cancers
Non-Small-Cell Lung Carcinoma
Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

Interventions: Drug: Decitabine
Biological: Depsipeptide
Drug: Celecoxib

First Posted Date: 2002-05-22

Last Posted Date: 2019-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00037817

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Saw Palmetto Extract in Benign Prostatic Hyperplasia

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

First Posted Date: 2002-05-17

Last Posted Date: 2010-01-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 224

Registration Number: NCT00037154

Locations: 🇺🇸
Northern California Kaiser Permanente, Oakland, California, United States
🇺🇸
Veterans Affairs Medical Center, San Francisco, California, United States

A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

Phase 2

Completed

Conditions: Diffuse Intrinsic Pontine Glioma

Interventions: Procedure: adjuvant therapy
Biological: pegylated interferon alfa

First Posted Date: 2002-05-13

Last Posted Date: 2012-02-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00036569

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy